Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer
Lymph Node Excision
Neoplasms, Germ Cell and Embryonal
Our data suggest that teratoma or viable NSGCT is present in approximately one-third of patients undergoing resection of residual ERP disease. The presence of residual ERP teratoma and viable NSGCT predicts for cancer progression independent of RP histology.